12:00 AM
 | 
Dec 09, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Nouriast istradefylline: Phase III started

Kyowa began a double-blind, placebo-controlled, international Phase III trial to evaluate 20 and 40 mg daily oral istradefylline for 12 weeks in about 609 patients with moderate to severe PD and wearing-off phenomena on levodopa therapy....

Read the full 160 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >